The case of development of bone toxicity, simulating a relapse of the underlying disease, in a child with neuroblastoma on the background of therapy with 13-cis-Retinoic acid
https://doi.org/10.17650/2311-1267-2018-5-2-60-65
Abstract
The article presents a case of development of bone tissue damage as a manifestation of toxicity against the background of differentiation therapy of 13-cis-Retinoic acid in a patient with neuroblastoma (NB) of a high-risk group. This clinical example is of interest as a model of a differential diagnosis of metastatic osseous lesion in patients with disseminated NB and a rare variant of bone toxicity during specific therapy.
About the Authors
G. B. Sagoyan
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
T. V. Shamanskaya
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
D. Yu. Kachanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
N. A. Bolshakov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
G. V. Tereshchenko
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
Yu. N. Likar
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
S. R. Varfolomeeva
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Goodman M.S., Gurney J.G., Smith M.A. еt al. Sympathetic nervous system tumors. In: Ries L.A.G., Smith M.A., Gurney J.G. (eds.). Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute, SEER Program. NIH Pub. No. 99- 4649. Bethesda, MD; 1999. Pp. 65–72.
2. Peinemann F., van Dalen E.C., Enk H., Berthold F. Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst Rev 2017;8:CD010685. doi: 10.1002/14651858.CD010685.pub3.
3. Spix C., Pastore G., Sankila R. et al. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42(13):2081–91. doi: 10.1016/j. ejca.2006.05.008.
4. Kushner B.H., LaQuaglia M.P., Bonilla M. A. et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994;12(12):2607–13. doi: 10.1200/JCO.1994.12.12.2607
5. Seeger R.C., Reynolds C.P. Neuroblastoma. In: Bone Marrow Transplantation. Edited by S.J. Forman, K.G. Blume, E.D. Thomas. Cambridg, England: Blacwell, 1994. Pp. 814–826.
6. Matthay K.K., Vallablanca I.G., Seeger R.S. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999;341(16):1165– 73. doi: 10.1056/NEJM199910143411601.
7. Ikeda H., August C.S., Goldwein J.W. et al. Sites of relapse in patient with neuroblastoma following bone marrow transplantation in relation to preparatory "debulking" treatments. J Pediatr Surg 1992;27(11):1438– 41. PMID: 1479507.
8. Villablanca J.G., Khan A.A., Avramis V.I. et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 1995;13(4):894–901. doi: 10.1200/ JCO.1995.13.4.894.
9. Gota V., Chinnaswamy G., Vora T. et al. Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients. Cancer Chemother Pharmacol 2016;78(4):763–8. doi: 10.1007/s00280-016-3126-3.
10. Matthay K.K. Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption. Clin Cancer Res 2013;19(2):311–3. doi: 10.1158/1078-0432.CCR-12-3313.
11. Cross S.F., Pozza L.D., Munns C.F. Hypercalcemia and osteoblastic lesions induced by 13-cis-retinoic acid mimicking relapsed neuroblastoma. Pediatr Blood Cancer 2009;53(4):666–8. doi: 10.1002/ pbc.22052.
12. Marabelle A., Sapin V., Rousseau R. Hypercalcemia and 13-cis-retinoic acid in post-consolidation therapy of neuroblastoma. Pediatr Blood Cancer 2009;52(2):280–3. doi: 10.1002/ pbc.21768.
13. DiGiovanna J.J. Isotretinoin effects on bone. J Am Acad Dermatol 2001;45(5):S176–82. doi: 10.1067/ mjd.2001.113721.
14. Atalay A., Altaykan A., Ergin G., Kutsal Y.G. Reversible sclerotic changes of lumbar spine and femur due to long-term oral Isotretinoin therapy. Rhuematol Int 2004;24(5):197–300. doi: 10.1007/s00296- 003-0391-3.
15. van Beek E., Löwik C., Karperien M., Papapoulos S. Independent pathways in the modulation of osteoclastic resorptioin by intermediates of the mevalonate biosynthetic pathway: The role of the retinoic acid receptor. Bone 2006;38(2):167–71. doi: 10.1016/j.bone.2005.08.011.
16. Suillington J., Choy L., Derynck R. Bone morphogenetic protein and retinoic acid signaling cooperate to induce osteoblast differentiation of preadipocytes. J Cell Biol 2002;159(1):135–46. doi: 10.1083/ jcb.200204060.
Review
For citations:
Sagoyan G.B., Shamanskaya T.V., Kachanov D.Yu., Bolshakov N.A., Tereshchenko G.V., Likar Yu.N., Varfolomeeva S.R. The case of development of bone toxicity, simulating a relapse of the underlying disease, in a child with neuroblastoma on the background of therapy with 13-cis-Retinoic acid. Russian Journal of Pediatric Hematology and Oncology. 2018;5(2):60-65. (In Russ.) https://doi.org/10.17650/2311-1267-2018-5-2-60-65
Views:
661
Email this article 